HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Abeona Therapeutics (NASDAQ: ABEO) and maintained a price target of $20 for the stock. This endorsement reflects confidence in the company's potential performance in the market.